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Abstract
Pancreatic cancer (PC) remains one of the most lethal human malignancies with poor prognosis. Despite all advances in
preclinical research, there have not been significant translation of novel therapies into the clinics. The development of
genetically engineered mouse (GEM) models that produce spontaneous pancreatic adenocarcinoma (PDAC) have increased
our understanding of the pathogenesis of the disease. Although these PDAC mouse models are ideal for studying potential
therapies and specific genetic mutations, there is a need for developing syngeneic cell lines from these models. In this
study, we describe the successful establishment and characterization of three cell lines derived from two (PDAC) mouse
models. The cell line UN-KC-6141 was derived from a pancreatic tumor of a KrasG12D;Pdx1-Cre (KC) mouse at 50 weeks of
age, whereas UN-KPC-960 and UN-KPC-961 cell lines were derived from pancreatic tumors of KrasG12D;Trp53R172H;Pdx1-Cre
(KPC) mice at 17 weeks of age. The cancer mutations of these parent mice carried over to the daughter cell lines (i.e.
KrasG12D mutation was observed in all three cell lines while Trp53mutation was observed only in KPC cell lines). The cell lines
showed typical cobblestone epithelial morphology in culture, and unlike the previously established mouse PDAC cell line
Panc02, expressed the ductal marker CK19. Furthermore, these cell lines expressed the epithelial-mesenchymal markers E-
cadherin and N-cadherin, and also, Muc1 and Muc4 mucins. In addition, these cell lines were resistant to the
chemotherapeutic drug Gemcitabine. Their implantation in vivo produced subcutaneous as well as tumors in the pancreas
(orthotopic). The genetic mutations in these cell lines mimic the genetic compendium of human PDAC, which make them
valuable models with a high potential of translational relevance for examining diagnostic markers and therapeutic drugs.
Citation: Torres MP, Rachagani S, Souchek JJ, Mallya K, Johansson SL, et al. (2013) Novel Pancreatic Cancer Cell Lines Derived from Genetically Engineered Mouse
Models of Spontaneous Pancreatic Adenocarcinoma: Applications in Diagnosis and Therapy. PLoS ONE 8(11): e80580. doi:10.1371/journal.pone.0080580
Editor: Fazlul H. Sarkar, Wayne State University School of Medicine, United States of America
Received August 20, 2013; Accepted October 14, 2013; Published November 20, 2013
Copyright: ß 2013 Torres et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was, in part, supported by grants from the NIH (TMEN U54 CA163120, EDRN UO1, CA111294, SPORE P50 CA127297, RO1 CA133774, RO1
CA78590, and RO3 CA167342). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sbatra@unmc.edu
. These authors contributed equally to this work.
Introduction
Despite many advances in the understanding of molecular
mechanisms involved in pancreatic cancer (PC) pathogenesis over
the last four decades, the disease remains one of the top
malignancies with worst prognosis [1]. These grim statistics are
a constant reminder of the urgent need for elucidating yet
undiscovered mechanisms of PC pathology that will contribute to
improved diagnosis and treatment regimens. For this purpose,
developing preclinical models is of vital importance, because they
are critical for evaluating novel therapeutic strategies [2].
Xenograft tumors in athymic nude mice are useful preclinical
models, but they cannot provide the role of immune mechanisms
that may add to or interfere with the action of the therapeutic
candidates. More recently, genetically engineered mice (GEM)
models that produce spontaneous pancreatic adenocarcinomas
(PDAC) have greatly advanced our understanding of PC
pathogenesis and also, allowed the examination of novel thera-
peutic approaches [3–6]. In addition, syngeneic cell lines can be
isolated from pancreatic tumors produced by GEM models and
used for in vitro and in vivo screening assays. The analysis of
functions and characteristics of specific genetic mutations and PC
biomarkers present in these cell lines can shed light on the design
of promising diagnostic and therapeutic strategies.
Mutations in KRAS, CDKN2A, TP53, and SMAD4/DPC4 genes
are commonly observed in PDAC tumors from PC patients [7]. In
consideration of these results, several mouse models that produce
spontaneous PDAC, have been engineered in the last decade
[3,4,6]. The present study focuses on mice carrying Kras and Trp53
mutations. The role of oncogenic Ras in PC was examined by
directing endogenous expression of KrasG12D in the progenitor cells
of the pancreas in KrasG12D;Pdx1-Cre (KC) mice [3], whereas the
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role of the endogenous expression of Trp53R172H and KrasG12D was
examined in the pancreas of KrasG12D;Trp53R172H;Pdx1-Cre
(KPC) mice [4]. The results indicate that the spontaneous
pancreatic tumors produced by these mouse models recapitulate
the clinical, histopathological and genomic features of human
PDAC.
Mouse PDAC cell lines with greater clinical relevance to PC are
highly needed. The currently available Panc02 cell line has been
used over the past three decades [8]. It was derived from PDAC
tumors induced by implanting 3-methyl-cholanthrene (3-MCA)-
saturated threads of cotton in the pancreas of C57BL/6 mice.
Despite its widespread use in evaluating various therapeutic
strategies, Panc02 cells lack strong clinical significance for PC due
to absence of mutational spectrum when compared to human
disease. Consequently, success in translating therapies indicated by
this model has been limited. In this manuscript, we describe the
generation and characterization of three new PDAC cell lines
derived from spontaneous mouse models of PC. One cell line was
derived from a KC mouse at 50 weeks age, and two others were
derived from KPC mice at 17 weeks of age. The successful
establishment and in vitro and in vivo characterization of these cell
lines are comprehensively described, including markers currently
known for pancreatic tumors.
Materials and Methods
Establishment of Cell Lines
The complete medium consisted of DMEM containing heat
inactivated FBS, L-Glutamine (200 mM), 100x non-essential
amino acids (100 mM), sodium bicarbonate, HEPES buffer,
Gentamicin (50 mg/ml), and Penicillin/Streptomycin (100 mg/
ml). Immediately after resecting the tumor, 200 mg of pancreatic
tumor tissue was transferred into a petri dish containing sterile
PBS and Gentamicin (20 mg/ml).
The collected tissues were washed 3 times with PBS-gentamicin
and transferred into a petri dish containing the complete medium.
The tumor was finely-minced with a sterile scalpel and transferred
into a sterile centrifuge tube with the complete medium containing
Collagenase P (Roche, Indianapolis, IN) (10 mg/ml).The mixture
was incubated at 37uC for 30 min. The tubes were inverted every
three min to ensure proper mixing. Following two washing cycles
in complete medium, the pellet obtained after centrifugation was
suspended in the complete medium. After letting the tube stand for
2 min, cell suspension without tissue debris was transferred into a
new sterile 10 cm Petri dish.
After incubating overnight at 37uC in 5% CO2, the medium
was replaced with fresh medium. Cells were trypsinized once
confluent. To prevent the growth of fibroblasts, differential
trypsinization was carried out, where trypsin was added to the
cells and after 10 sec, the cells were washed with PBS and fresh
medium was added. Additionally, medium was supplemented with
cholera toxin (400 ng/ml) for the first 7 passages as it has been
previously reported that it has an enhanced mitogenic effect on
epithelial cells, but not on fibroblast cells [9]. After 10 passages, the
cell lines were transferred to normal complete medium (i.e.
DMEM medium supplemented with 10% FBS, 100 mg/ml
penicillin, 100 mg/ml streptomycin) and maintained at 37uC and
5% CO2 in a humidified incubator. Three cell lines were
established successfully. The cell line derived from a
KrasG12D;Pdx1-Cre (KC) mouse was named UN-KC-6141 and
the two cell lines derived from KrasG12D;Trp53R172H;Pdx1-Cre
(KPC) mice were named UN-KPC-960 and UN-KPC-961 (UN
designates University of Nebraska Medical Center). In vitro
characterization and tumorigenic studies were done after 35
passages in cell culture. The murine PDAC cell line Panc02 was
included in the in vitro functional assays.
Sequencing of Cell Lines for Kras and p53 Mutations
The sub-confluent cultures of UN-KC-6141, UN-KPC-960,
and UN-KPC-961 were lysed with cell lysis solution containing
beta-mercaptoethanol and total RNA was isolated with RNeasy
Minikit (Qiagen, Germantown, MD). cDNA was synthesized from
total RNA using oligo(dT)18 primer and SuperScript II reverse
transcriptase (Life technologiesTM, Carlsbad, CA). PCR amplifi-
cation of murine Kras codon 12 (exon 1) and p53 codons 172 (Exon
5) was carried out by using set of primers to each gene (Kras-
seqF:5’-ACTTGTGGTGGTTGGAGCTG-3’, Kras-seqR:5’-
TGACCTGCTGTGTCGAGAAT-3’, p53-seqF: 5’-CACG-
TACTCTCCTCCCCTCA-3’ and p53-seqR: 5’-ATTTCCTTC-
CACCCGGATAA-3’), which results in a 168 bp (Kras) and 229 bp
(p53) PCR products. The PCR products were purified with PCR
product purification kit (Qiagen, Germantown, MD) and the
purified PCR products were sequenced using Kras-seqR:
5’-TGACCTGCTGTGTCGAGAAT-3’ for Kras and p53-seqF:
5’-CACGTACTCTCCTCCCCTCA-3’ for p53 gene.
Growth Kinetics
For growth kinetics studies, each cell line was seeded in
quadruplicate in a 96-well plate (1,000 cells/well) in complete
medium. After overnight incubation, the medium was replaced
with medium supplemented with 1% FBS and Penicillin/
Streptomycin (100 mg/ml). Every day, 10 ml of the Cell Prolifer-
ation Reagent WST-1 (Roche, Indianapolis, IN) was added to
each well and after 3 h of incubation, absorbance values were
measured at 450 nm. Absorbance values were subtracted from
values recorded at the reference wavelength (600 nm), as indicated
by the manufacturer. The procedure was repeated for 7 days. The
doubling time (TD) for each cell line was calculated during the
exponential growth phase using the formula TD=0.693t/ln(Nt/
N0), where t = time difference in h, Nt=absorbance value at time
t, and N0=absorbance value at initial time [10].
Real Time PCR
RNA was isolated and purified from UN-KC-6141, UN-KPC-
960, UN-KPC-961, Panc02, and NIH3T3 (mouse fibroblasts) cells
using the RNeasy Minikit (Qiagen, Germantown, MD). cDNA
was synthesized from total RNA using oligo(dT)18 primer and
SuperScript II reverse transcriptase (Life technologiesTM, Carls-
bad, CA) as described by us in a previous publication [11]. Real-
time PCR was carried out in the LightCycler 480 (Roche
Diagnostics, Indianapolis, IN). The amplification was done in a
two-step process (95uC for 5 min followed by 45 cycles of 95uC for
10 sec, 60uC for 10 sec, and 72uC for 10 sec) using the LightCycler
480 SYBR Green I Master Mix (Roche Diagnostics, Indianapolis,
IN) and cDNA from each sample. GAPDH was used as the internal
control gene to which all genes were normalized. The fold-change
in gene expression of Amylase and CK19 mRNA in cancer cell lines
were compared relative to mRNA levels extracted from normal
mouse pancreas using the 22DDCt method, whereas the fold-
change of Muc1 and Muc4 were compared relative to mRNA
extracted from the mouse fibroblast cell line NIH3T3. The
sequence of the primers used in this study are listed in Table 1.
Antibodies
The anti-CK19 hybridoma (TROMA-III) developed by Dr.
Rolf Kemler was obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD
PDAC Cell Lines Derived from GEM Models
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and maintained at The University of Iowa (Iowa City, IA).
Antibody against murine E-cadherin was obtained from Cell
Signaling (Danvers, MA). N-cadherin antibody was a kind gift
from Dr. Keith R. Johnson from UNMC (Omaha, NE). b-actin
and Amylase antibodies were purchased from Sigma Aldrich (St.
Louis, MO). For confocal studies the secondary antibodies
conjugated to Alexa FluorH (568, 488) were obtained from Life
TechnologiesTM (Carlsbad, CA). The secondary antibodies
conjugated to horseradish peroxidase used for western blot
analysis were obtained from GE Healthcare Life Sciences
(Uppsala, Sweden). Anti-mouse Muc1 antibody (mouse monoclo-
nal antibody recognizing the cytoplasmic tail of Muc1) was
purchased from AbcamH (Cambridge, MA, USA). The anti-Muc4
(4A-rabbit polyclonal) antibody was designed in this lab and
developed by GenScript (Piscataway, NJ, USA) as has been
described previously [12].
Confocal Microscopy
Protein expression was analyzed by confocal microscopy. 26105
cells suspended in complete medium were seeded on glass cover
slips placed in a 12-well plate. The next day, cells were fixed in ice
cold methanol. After washing in PBST and blocking with 10%
goat serum (Jackson Immunoresearch Labs, West Grove, PA), the
cells were incubated with antibodies for Amylase (1:500), CK19
(1:1,000), E-cadherin (1:50), N-cadherin (1:20), and Muc1 (1:100)
overnight. They were washed four times with PBST, 5 min per
wash. The cells were incubated with the respective secondary
antibodies (mouse/rabbit) conjugated to Alexa Fluor (568, 488)
(Life TechnologiesTM, Carlsbad, CA) and after repeating the
washing steps, the glass coverslips were mounted on glass slides
with vectashield mounting medium (Vector Laboratories, Burlin-
game, CA). The cells were imaged on a laser confocal microscope
LSM 510 (Carl Zeiss GmbH, Thornwood, NY) in the respective
wavelengths at a magnification of663.
Western Blot Analysis
For western blot analysis, cells were seeded on each well of a 6-
well plate in complete medium. At ,80% confluency, cells were
lysed with radioimmunoprecipitation assay buffer (RIPA) contain-
ing protease and phosphatase inhibitors. The lysates were
subjected to several freeze-thaw cycles to ensure complete lysis.
The concentration of lysates was determined with the micro–
bicinchoninic acid protein estimation kit (Bio-Rad, Hercules, CA).
The protein concentrations were adjusted and solutions were
prepared under reducing conditions (i.e. b-mercaptoethanol). 2%
SDS-agarose gels were used for analysis of Muc4 expression. 40 mg
of protein lysates were loaded and the gel was run for 4 h at 100 V.
E-cadherin and N-cadherin expression levels were analyzed by
SDS-PAGE. 40 mg of protein lysates were loaded and separation
was done at 80 mA for 1 h. Resolved proteins were transferred
onto polyvinylidene difluoride membranes, blocked in 5% milk in
PBS, and incubated with the primary antibodies overnight. After
washing with PBST, the corresponding secondary antibodies were
added and after repeating the washing steps, the proteins were
detected by luminol (Thermo Scientific, Middletown, VA) after
exposure to X-ray films.
Cytotoxic Assay
The cytotoxic effect of the chemotherapeutic drug Gemcitabine
on KC and KPC cell lines was compared to the cytotoxic effect on
Panc02. The injectable solution of Gemcitabine, GEMZARH (Eli
Lilly Company, Indianapolis, IN) was kindly provided by the
pharmacy at the Lied Transplant Center at UNMC. For the
cytotoxic assay, 16104 cells suspended in complete medium were
seeded in each well of a 96-well plate. The next day, the cells were
treated with different concentrations of Gemcitabine solution
(100 nM-100 mM) in quadruplicate wells. After incubating the
cells with Gemcitabine for 48 h, media containing thiazolyl blue
tetrazolium bromide reagent (Sigma Aldrich, St Louis, MO) was
added to the cells. After 4 h of incubation, the formazan crystals
produced by metabolically active cells were dissolved with 100 ml
of DMSO. Absorbance values at 540 nm were used to calculate
cytotoxicity percentages. The half maximal inhibitory concentra-
tion (IC-50) of Gemcitabine was determined in each cell line from
interpolating values in the graph (% Cytotoxicity vs. Gemcitabine
Concentration).
Tumorigenicity studies
The tumorigenicity of the cell lines was determined after
orthotopic implantation of the mouse PC cell lines (UN-KC-6141/
UN-KPC-960/UN-KPC-961) into the head of the pancreas after
35 passages. Based on the mice background from where the cell
lines were generated, UN-KC-6141 cells (16106) were injected in
C57BL/6 mice, whereas UN-KPC-960 and UN-KPC-961 cells
(16106) were injected in mixed background (i.e. B6.129) mice
(N= 7). Mouse PC cells suspended in 50 ml sterile PBS were
injected orthotopically using the same procedure described by us
[13,14]. Subcutaneous tumor growth was evaluated with the UN-
KPC-961 cell line only. 56106 cells were injected (N= 12) in
mixed B6.129 background mice on the lateral chest. Tumor
growth was monitored by palpation/Vernier caliper measure-
ments in case of subcutaneous tumors. Throughout the experi-
ment, animals were provided with food and water ad libitum and
subjected to a 12-h dark/light cycle. Animal studies were
performed in accordance with the U.S. Public Health Service
"Guidelines for the Care and Use of Laboratory Animals" under
an approved protocol by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee (IACUC).
After euthanization, pancreatic tumors were dissected out,
weighed and fixed in 10% formalin (Fisher Scientific, Fair Lawn,
NJ) for H&E staining. Gross metastatic lesions were examined in
distant organs and processed for histological analysis.
Hematoxylin and eosin staining (H&E)
After fixing tissues in 10% formalin for at least 48 h, the tissues
were embedded in paraffin and serial tissue sections (4 mm thick)
Table 1. Primer sequences used for real time PCR analysis.
Mouse Gene Primer Sequence
Amylase FP – 59-CAAAATGGTTCTCCCAAGGA-39
RP – 59-ACATCTTCTCGCCATTCCAC-39
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were cut. The sections were deparaffinized using EZ-DeWaxTM
(Bio genex, San Roman CA, USA) and rehydrated progressively.
Afterwards, the sections were stained with hematoxylin and eosin
(H&E) stains and examined by a certified pathologist.
Statistics
Significant differences in the experimental values were deter-
mined by calculating p-values using the JMPH Statistical Discovery
Software (Cary, NC). A Student’s t-test was used to calculate the
corresponding p-value (p-values , 0.05 were considered statistically
significant).
Figure 1. In vitro establishment of KC and KPC cell lines. (A) Inverted microscope images (4X) of UN-KC-6141, UN-KPC-960, and UN-KPC-961
PDAC cell lines after 35 passages. The three cell lines displayed typical cobblestone epithelial morphology. Genetic sequence analysis of (B) KrasG12D
and (C) Trp53R172H mutation in mouse PC cell lines. Blue shaded areas represent the codon where the mutation is located. A yellow rectangle indicate
the nucleotide responsible for the mutation. A pancreas from a Pdx1-Cre mouse (mouse tag UN-KPC-1207) was used as a negative control for Kras
mutation.
doi:10.1371/journal.pone.0080580.g001
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Results
In vitro establishment of KC and KPC cell lines
Mouse PC cell lines were successfully generated from the
spontaneous pancreatic tumors produced by the KrasG12D;Pdx1-
Cre (KC) and the KrasG12D;Trp53 R172H;Pdx1-Cre (KPC) mice at
50 weeks and 17 weeks of age, respectively. One cell line derived
from the KC mice was named UN-KC-6141, and two other cell
lines derived from the KPC mice were named UN-KPC-960 and
UN-KPC-961. All three cell lines grew for over 50 passages in
normal media with no sign of senescence. Monolayer cultures of
all three cell lines showed typical cobblestone morphology with
closed contact island formation (Fig 1A). To verify that these cell
lines maintained the genetic mutations of their respective parental
mice (KC and KPC), the mutational status of the Kras (Fig. 1B)
and Trp53 (Fig. 1C) loci was examined. As expected, all three cell
lines carried the KrasG12D point mutation, whereas UN-KPC-960
and UN-KPC-961 carried the Trp53R172H activating mutation.
The growth kinetics of these three mouse PC cell lines were
compared with Panc02 cells (Fig 2A). UN-KPC-961 cells
proliferated the fastest with a doubling time (TD) of 33 h (p ,
0.0001 compared to Panc02). UN-KPC-960 and Panc02 grew at
similar rates (TD < 60 h), while UN-KC-6141 showed the slowest
growth rate (TD of 70 h) (Fig 2B).
Figure 2. Growth kinetics of mouse PDAC cell lines. (A) Cells were seeded in quadruplicate wells of 96-well plates and their growth was
followed every day by measuring absorbance after incubation with WST-1 reagent. Data is represented as the mean absorbance (lSample = 450 nm,
lRef = 600 nm) of four replicates 6 standard error. Statistics were calculated in comparison to the growth curve for Panc02 (*p , 0.01, **p , 0.001,
***p , 0.0001). (B) Doubling time (TD) of cell population was calculated using the equation TD= (0.693t)/ln(Nt/N0) where t = time difference in h
during log phase, Nt = absorbance value at time t, and N0 = absorbance value at initial time.
doi:10.1371/journal.pone.0080580.g002
PDAC Cell Lines Derived from GEM Models
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KC and KPC-derived cell lines have ductal-like
characteristics
PDACs are thought to arise from the epithelial cells of the
pancreatic duct [7]. The exocrine pancreas contains both acinar
and ductal cells. Pancreatic acinar cells are characterized by
amylase expression and lack of expression of either cytokeratin 19
(CK19) or mucins, and the ductal cells are characterized by
expression of CK19 and mucins but no expression of amylase
[15,16]. Indeed, previous studies have reported pancreatic tumors
from KC and KPC mice expressed CK19 and frequently, mucin,
indicating their ductal heritage [3,4]. To validate whether our KC
and KPC derived-cell lines had these ductal characteristics, we
examined amylase and CK19 expression by real time PCR and
confocal microscopy. Panc02 cells were included in these analyses
for comparison, and normal pancreatic tissue was used for
estimating relative gene expression. Real-time PCR experiments
Figure 3. Ductal characteristics of KC and KPC cell lines. (A) Real-time PCR analysis of Amylase and CK19 in mouse PDAC cells. These mRNA
transcripts were compared relative to the mRNA levels in normal pancreas. The data represents the mean fold increase of three replicates6 standard
error. Statistics were calculated in comparison to normal pancreas (*p , 0.005, **p , 0.0001). (B) The protein expression of Amylase and CK19 were
evaluated on mouse PDAC cell lines by confocal analysis. Amylase was visualized after staining with a secondary antibody conjugated to Alexa FluorH
568 (Red Fluorescent) and CK19 was visualized after staining with Alexa FluorH 488 (Green Fluorescent). Cell nuclei were stained with DAPI.
doi:10.1371/journal.pone.0080580.g003
PDAC Cell Lines Derived from GEM Models
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showed high expression of the CK19 ductal marker in our three
new PDAC cell lines (p , 0.005) compared to Panc02 (Fig. 3A).
To our surprise, Panc02 cells did not show any CK19 expression,
even though it has been referenced as a murine ductal PDAC cell
line for nearly three decades [8]. None of the four cell lines showed
amylase expression, whereas normal pancreas expressed this
acinar marker. These results were further confirmed by confocal
microscopy analysis (Fig. 3B).
KC and KPC cell lines have epithelial-mesenchymal
characteristics
The epithelial-mesenchymal transition induces loss of cell
adhesion, which corresponds to E-cadherin downregulation and
increased expression of N-cadherin, leading to the initiation of
PDAC metastasis [17]. We examined E-cadherin and N-cadherin
expression by confocal microscopy and western blot analyses in
the three newly-established KC and KPC cell lines. E-cadherin
expression was observed in UN-KC-6141, UN-KPC-960, and
UN-KPC-961 cells, indicative of their epithelial nature (Fig. 4A-
B). In contrast, Panc02 cells showed minimal E-cadherin
expression. The pattern of N-cadherin expression was similar,
being more prominent in the KC and KPC cell lines, compared to
the expression in Panc02 cells (Fig. 4C-D).
KC and KPC cell lines express high levels of Muc1 and
Muc4
Different types of mucins are expressed in the pancreas during
PC progression [12,18]. Furthermore, PC precursor lesions in
genetically engineered mouse PDAC models such as the KC and
KPC mice, are known to produce mucins [3,4]. Recently, we also
have demonstrated that in the pancreas of KC mice, expression of
Muc1, Muc4, and Muc5AC progressively increased in correlation
with PDAC development [12]. We examined whether the
expression of these mucins can be corroborated in the KC and
KPC-derived cell lines. To this end, real-time PCR, western blot,
and confocal microscopy analyses were conducted. The results
indicated that relative transcript levels of the transmembrane
mucins Muc1 (p , 0.001) and Muc4 (p , 0.05) were significantly
Figure 4. Epithelial-mesenchymal characteristics of KC and KPC cell lines. (A) Confocal microscopy images of E-cadherin (Alexa FluorH 568,
Red Fluorescent) expression in mouse cell lines. Cell nuclei were stained with DAPI. (B) Western blot analysis of E-cadherin in mouse cell lines. Protein
lysates were resolved by 10% SDS-PAGE. b-actin was used as loading control. (C) Confocal microsocopy images of N-cadherin (Alexa FluorH 488,
Green Fluorescent) expression in mouse cell lines. Cell nuclei were stained with DAPI. (D) Western blot analysis of N-cadherin in mouse cell lines.
Protein lysates were resolved by 10% SDS-PAGE. b-actin was used as loading control.
doi:10.1371/journal.pone.0080580.g004
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higher in UN-KC-6141, UN-KPC-960 and UN-KPC-961 cells
(Fig. 5A) compared to control cells (NIH3T3 fibroblasts). In
Panc02 cells, the relative transcript levels of Muc1 and Muc4 were
elevated, but they were not statistically significant. Nevertheless,
Panc02 cells and the two cell lines derived from KPC mice showed
higher levels of Muc4 protein than the KC-derived cell line
(Fig. 5B). On the other hand, Muc1 protein in Panc02 was lower
than in the KC and KPC-derived cells (Fig. 5C). To our surprise,
Muc5AC was not detectable in any of the cell lines, either at
transcript or at protein levels (data not shown), and this may be a
consequence of evolutionary changes associated with cell culture.
KC and KPC cell lines are resistant to Gemcitabine
Despite recent reports that PC patients show greater survival
when treated with FOLFIRINOX (a combination of oxaliplatin,
irinotecan, fluorouracil and leucovorin) instead of Gemcitabine
Figure 5. Mucin expression in mouse PDAC cell lines. (A) Real time PCR analysis of Muc1 and Muc4 in mouse PDAC cell lines. The mRNA
transcripts were normalized to mRNA levels in the mouse fibroblast cell line NIH3T3. The data represents the mean fold increase of three replicates 6
standard error. Statistical significances were calculated in comparison to NIH3T3 (*p , 0.05, **p , 0.001, ***p , 0.0001). (B) Western blot analysis of
Muc4 in mouse cell lines. Protein lysates for Muc4 analysis were resolved by 2% SDS agarose gels. b-actin was used as a loading control and it was
resolved in 10% SDS-PAGE. (C) Confocal microscopy images of Muc1 (Alexa FluorH 568, Red Fluorescent) expression in mouse cell lines. Cell nuclei
were stained with DAPI.
doi:10.1371/journal.pone.0080580.g005
PDAC Cell Lines Derived from GEM Models
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[19], the latter is still the most used drug in PC chemotherapy
[20]. Therefore, using the MTT assay, we examined Gemcitabine
cytotoxicity on UN-KC-6141, UN-KPC-960, UN-KPC-961 and
Panc02 cells (Fig. 6A). Panc02 cells were the most Gemcitabine-
resistant with a half maximal inhibitory concentration (IC-50) of
15 mM after 48 h of treatment (Fig. 6B). The IC-50 values of the
KC and KPC cell lines ranged from 0.5 mM to 5 mM. Although
Panc02 cells were more resistant to Gemcitabine, these IC-50
values are in the comparable range of human PC cells [21,22].
Interestingly, at higher Gemcitabine concentrations (30–100 mM)
(Fig. 6A), the UN-KPC-961 cells showed greater Gemcitabine
resistance than the Panc02 cells.
Figure 6. Cytotoxic effects of Gemcitabine in mouse PDAC cell lines. (A) Gemcitabine cytotoxicity in mouse PDAC cell lines was determined
by the MTT cytotoxic assay. Cells were seeded in quadruplicate wells and incubated with different concentrations of Gemcitabine (100 nM–100 mM)
for 48 h. After replacing media with the MTT reagent and dissolving the formazan crystals with DMSO, cytotoxicity was calculated based on the
absorbance values (l = 540nm) in cells treated with media only. The presented data are average of cytotoxicities in quadruplicate wells 6 standard
error. Statistical significance was calculated in comparison to Panc02 (*p , 0.01, **p , 0.001, ***p , 0.0001). (B) The half maximal inhibitory
concentration (IC-50) of Gemcitabine in each cell line was determined after interpolation in the graphs of %Cytotoxicity vs. Concentration.
doi:10.1371/journal.pone.0080580.g006
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Transplanted KC and KPC cell lines induce pancreatic
tumors in mice
The establishment of the KC and KPC cell lines in culture
provided the opportunity to examine their tumorigenicity in
appropriate mouse background from which they were derived.
The UN-KC-6141 cells were tested in the C57BL/6 mice, while
UN-KPC-960 and UN-KPC-961 cells were examined in mice of
mixed B6.129 background. One month after orthotopic implan-
tation of UN-KC-6141 cells in C57BL/6 mice, tumors formed in
their pancreas (Fig. 7A), and metastatic lesions in liver, spleen,
small intestines, mesenteric lymph nodes and peritoneal wall were
observed. Tumor incidence for UN-KC-6141 cells was 100%. The
two KPC-derived cells (UN-KPC-960 and UN-KPC-961) also
Figure 7. Tumorigenicity of KC and KPC cell lines. (A) The tumorigenic properties of UN-KC-6141, UN-KPC-960, and UN-KPC-961 cells were
evaluated after orthotopic (OT) (N = 7) implantation of 16106 cells in the respective mice background. Subcutaneous (SC) injections of UN-KPC-961
cells (56106 cells) were also performed. OT tumors were grown for different time intervals: one month for UN-KC-6141 and two months for UN-KPC-
960 and UN-KPC-961. SC tumors were grown for three weeks. Data is represented as the average weight of pancreatic tumors 6 standard error.
Differences in tumor size after mice euthanization were not statistically significant. (B) Hematoxylin & eosin stained tumor sections (10X) from UN-
KPC-961 cells after OT implantation (left) and SC implantation (right). The tumors presented characteristics of poorly differentiated adenocarcinoma.
doi:10.1371/journal.pone.0080580.g007
Table 2. Summary of protein expression in murine PDAC cell
lines.





Panc02 – – – – + + –
UN-KC-6141 – + + + + + –
UN-KPC-960 – + + + + + –
UN-KPC-961 – + + + + + –
doi:10.1371/journal.pone.0080580.t002
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formed tumors after orthotopic implantation (Fig. 7A), but those
appeared at slower rates and the tumors took over two months to
grow. The comparatively slower tumor growth kinetics of the KPC
cells may have been caused by genetic differences between KC
and KPC cells, as well as the different backgrounds of their
respective host mice. Interestingly, the UN-KPC-961 cells
appeared to be more tumorigenic (tumor incidence 86%) than
the UN-KPC-960 cells (tumor incidence 43%). These results are in
agreement with their growth kinetics (i.e. UN-KPC-961 showed
faster growth than UN-KPC-960). In addition, UN-KPC-961-
derived tumors appeared to be more aggressive, showing
metastasis to spleen, stomach, liver, and diaphragm, whereas the
UN-KPC-960-derived tumors did not show any metastatic lesions.
When UN-KPC-961 PC cells were injected subcutaneously into
the mixed B6.129 background mice, all mice developed tumors in
three weeks, but no metastases were observed. Figure 7A shows a
comparison of tumors derived from these experiments. Although
the average weights of the orthotopic tumors derived by the UN-
KPC-960 cells were smaller, tumor weight differences across all
groups were not statistically significant. Further, we also performed
subcutaneous injection using UN-KC-6141 and UN-KPC-960 PC
cells into two C57BL/6 and B6.129 background mice and all the
mice developed tumors after 4 weeks (data not included).
For PDAC, histological grading is assigned by the extent of
glandular differentiation [23]. If over 95% of a tumor is composed
of glands then it is classified as well differentiated, if that extent is
50–95%, a tumor is considered moderately differentiated, and if
less than 50%, a tumor is described as poorly differentiated.
Histologic analyses classified the KC and KPC-derived tumors as
moderately to poorly differentiated tumors, because they did not
show duct formation (Fig. 7B). In fact, most of these tumors
presented characteristics of poorly differentiated (grade III)
adenocarcinoma. These results are different from previous studies
reporting that most spontaneous pancreatic tumors from KC and
KPC mice show moderately well-differentiated to well-differenti-
ated morphology [3,4].
Discussion
Genetically engineered mouse models are presently a promising
approach for understanding the pathogenesis and progression of
PDAC and for evaluating novel therapeutic agents (natural/
synthetic) that should translate to high clinical success [24].
Unfortunately, the generation and maintenance of these advanced
models require a high cost and time investment. PDAC cell lines
from these model mice should have a major role in facilitating
screening and prioritization of the variables (e.g. study gene roles
or novel therapies), before the ideas are evaluated in the more
expensive mouse models.
To our knowledge, this is the first paper reporting the successful
establishment and characterization of PDAC cell lines derived
from KrasG12D;Pdx1-Cre (KC) and KrasG12D;Trp53R172H;Pdx1-
Cre (KPC) mouse models. The three cell lines derived in these
studies, named UN-KC-6141, UN-KPC-960, and UN-KPC-961,
have been maintained in cell culture for over 50 passages without
any sign of senescence. These cell lines show typical epithelial
cobblestone morphology, and expressed high levels of epithelial
and mesenchymal markers such as CK19, E-cadherin, N-
cadherin, Muc1, and Muc4 (Table 2). Although Panc02 has
been classified as a PDAC cell line on the basis of histological
analysis since its establishment three decades ago [8], we noted
with interest that it does not express the ductal marker CK19,
which raises questions about its phenotype (Table 2). Further-
more, unlike the KC and KPC cell lines, Panc02 cells did not
express E-cadherin and N-cadherin. As differential levels of these
cadherins have a major role in metastasis [17], these cell lines
should be useful for evaluating various therapeutic agents or study
the fuction of various genes by manipulation.
The most commonly occurring mutations in PDAC include
those in the KRAS, CDKN2A, TP53, and SMAD4/DPC4 genes [7].
Mutations in the KRAS gene are present in 90% of PDAC [25],
TP53 mutations occur in ,75% of PDAC [26], and 55% of
pancreatic tumors have SMAD4/DPC4 deletions or mutations
[27]. The KC and KPC-derived cell lines described here did not
suffer from evolutionary changes in their cancer genes. Sequencing
of these cell lines for point mutations in KRAS and P53 genes
revealed the presence of Kras point mutations (Gly-Asp) in all the
KC and KPC-derived cell lines, and the Trp53 mutation (R172H)
was only present only in the KPC cell lines. Two recent
publications have reported the well-established Panc02 cell line
has a Smad4 mutation, but both Kras and Trp53 mutations are
absent [28,29]. Considering that human PDAC show higher
frequency of KRAS and TP53 mutations and ductal characteristics,
the newly derived murine PDAC cell lines UN-KC-6141, UN-
KPC-960, and UN-KPC-961 should be very valuable preclinical
studies and have excellent translational significance.
Gemcitabine is the most used chemotherapeutic treatment for
PC patients, but tumors may acquire resistance, as evidenced by
the poor survival statistics [30]. Some studies have shown that
epithelial to mesenchymal transition contributes to drug resistance
in PC cells [31,32]. In one of these studies it was documented that
E-cadherin levels in cancer cells have an inverse correlation with
drug resistance [32]. This may explain why Panc02 was more
resistant to the effects of Gemcitabine (IC-50 = 15 mM) when
compared to the spontaneous PDAC cell lines (IC-50s = 0.5–
5 mM). The expression levels of E-cadherin in UN-KC-6141, UN-
KPC-960, and UN-KPC-961 cells correlated with decreased drug
resistance. It is important to note that even though the KC and
KPC-derived PDAC cell lines were not as resistant to Gemcitabine
as the Panc02 cells, these cytotoxicity levels are in the range of
those found in human PDAC cell lines [21,22].
In conclusion, the UN-KC-6141, UN-KPC-960, and UN-KPC-
961 cells described here represent a valuable tool for yielding a
better understanding of PC pathogenesis and to study novel
treatments for this lethal disease. The genotypic and phenotypic
characteristics of these novel cell lines mimic human PDAC, which
make them valuable models with significant translational rele-
vance.
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